Table 5.
Odds ratios for achieving remission
| Variable | OR | 95% CI | p value |
|---|---|---|---|
| Model 1 | |||
| Sex (men vs. women) | 1.30 | 1.10–1.53 | 0.002 |
| Age (<65 vs. ≥65 years of age) | 1.43 | 1.23–1.65 | <0.001 |
| Steinbrocker functional class (1–3 vs. 4) | 2.41 | 1.30–4.49 | 0.006 |
| Duration of RA (years) | |||
| <5 vs. ≥15 | 1.62 | 1.36–1.92 | <0.001 |
| 5–10 vs. ≥15 | 1.17 | 0.97–1.42 | 0.098 |
| 10–15 vs. ≥15 | 1.04 | 0.84–1.28 | 0.733 |
| DAS28 at baseline (moderate vs. high) | 2.95 | 2.59–3.37 | <0.001 |
| Concomitant use of MTX | |||
| <8 mg/week vs. none | 1.30 | 1.13–1.49 | <0.001 |
| ≥8 mg/week vs. none | 1.74 | 1.32–2.28 | <0.001 |
| Previous treatment with infliximab (yes vs. no) | 0.65 | 0.53–0.81 | <0.001 |
| Model 2a | |||
| Presence of combined risk factorsb | |||
| 4 vs. 0–1 | 6.30 | 4.83–8.21 | <0.001 |
| 3 vs. 0–1 | 3.20 | 2.64–3.88 | <0.001 |
| 2 vs. 0–1 | 1.87 | 1.55–2.26 | <0.001 |
Multiple logistic regression models [for all cases, n = 6763 (79 patients with low disease activity were excluded) and for remission cases, n = 1234]
DAS28 modified disease activity score including a 28-joint count, MTX methotrexate, OR odds ratio, RA rheumatoid arthritis
aResults were adjusted for sex, age, and previous treatment with infliximab
bCombined factors: Steinbrocker functional class = 1–3; MTX = yes; baseline DAS28 = >3.2 and ≤5.1 (moderate disease); duration of RA <5 years; p < 0.001 for linear trend using the Wald test